Clinical Study
Clinical Practice Associated with a Switch from and to Ziprasidone during Routine Inpatient Treatment of Patients with Schizophrenia
Table 1
Switch from or to ziprasidone: clinical data.
| | ZIP+ switch to ziprasidone | ZIP− switch from ziprasidone | Difference |
| | 24 | 27 | n.s.b | | Diagnoses (ICD-10) | | | n.s.b | | F20.0 | 18 (75.0%) | 21 (77.8%) | | | F20.1 | 2 (8.3%) | 1 (3.7%) | | | F20.3 | 4 (4.2%) | 3 (11.1%) | | | F20.4 | 0 | 2 (7.4%) | |
| | Comorbidity (ICD-10) | | | | | None | 6 (25.0%) | 16 (59.3%) | | | 1 | 11 (45.8%) | 9 (33.3%) | | | 2 | 7 (29.2%) | 2 (7.4)%) | | | F1 substance abusec | 12 (50.0%) | 8 (29.6%) | n.sb | | F43 adjustment disorder | 6 (25.0%) | 2 (7.4%) | | | F60 personality disorder | 2 (8.3%) | 1 (3.7%) | n.s.b |
| | Women | 16 (67%) | 10 (37%) |
b | | Age | 40.6 (8.9) | 47.2 (10.3) |
a | | BMI at admission (kg/m²) | 26.9 (3.2) | 25.1 (2.7) |
a | | Women | 26.9 (3.8) | 24.0 (2.4) |
a | | Men | 26.8 (1.5) | 25.7 (2.8) | n.sa | | Switch modalities | | | | | Start/stop (abrupt change) | 16 (67%) | 17 (63%) | n.s.b | | Tapering time (days) | 2.3 (3.5) | 2.4 (3.6) | n.s.a | | Illness duration (years) | 14.3 (7.8) | 16.4 (10.0) | n.s.a | | Hospitalization (days) | 40.0 (21.2) | 46.1 (43.7) | n.s.a |
| | Ziprasidone dose | 140.8 (27.8) | 136.3 (38.0) | n.s.a | | Minimum | 80 | 80 | | | Maximum | 180 | 240 | | | CPZE before switch | 889 (291) | 681 (190) |
a | | CPZE after switch | 704 (140) | 831 (340) |
a |
| | Psychotropic comedication: none | 5 (20.8%) | 5 (18.5%) | n.s.b |
| | Laboratory abnormalitiesd | 3 (12.5%) | 1 (3.7%) | n.s.b | | ECG abnormalitiese | 4 (16.7%) | 4 (14.8%) | n.s.b | | QTc prolongation >460 msec | 0 | 0 | n.s.b |
| | Severity at admission | 5.3 (0.61) | 5.2 (0.64) | n.s.a | | Severity at discharge | 3.2 (0.89) | 3.0 (0.85) | n.s.a | | Change severity | 2.0 (0.95) | 2.2 (1.08) | n.s.a |
| | Side effects at admission | 1.1 (0.88) | 0.9 (0.70) | n.s.a | | Side effects at discharge | 0.5 (0.59) | 0.6 (0.64) | n.s.a | | Change side effects | 0.5 (0.78) | 0.3 (0.62) | n.s.a |
|
|
-test (independent groups); b test; cF1 including alcohol abuse/dependence, THC abuse/dependence, benzodiazepine dependence, opioid abuse, multiple substance abuse (excluded: nicotine dependence); dZIP+: creatine kinase (2-fold), hyperglycemia, yGT (189 U/L); ZIP−: serum creatinine (1.4 mg/dL); eZIP+: AVB I°, repolarisation disturbance, nonspecific conduction disturbance (2); ZIP−: AVB I° (2), nonspecific conduction disturbance, abnormal repolarisation; n.s.: not significant; severity of illness was judged by 7-point ratings (CGI), side effects by a global severity rating (0–3).
|
